Carbidopa monohydrate

Names

[ Name ]:
Carbidopa monohydrate

[Synonym ]:
Benzenepropanoic acid, α-hydrazinyl-3,4-dihydroxy-α-methyl-, (αS)-, hydrate (1:1)
CARBIDOPA 1-HYDRATE,PHARMA
Carbidopa
(S)-Carbidopa
1-a-(3,4-Dihydroxybenzyl)-a-hydrazinopropionic Acid
L-a-Methyldopahydrazine
(aS)-a-Hydrazino-3,4-dihydroxy-a-methylbenzenepropanoic Acid
CARBIDOPA MONOHYDRATE
(S)-(-)-CARBIDOPA MONOHYDRATE
a-Methyldopahydrazine
Lodosin
carbidopa [INN_en]
CARBIDOPA HYDRATE
CARBIDOPA(GMP CERTIFICATE)
(S)-(-)-Carbidopa
HMD
CARBIDOPA,USP
(2S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid hydrate (1:1)
(2S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid
S-(−)-Carbidopa
(S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropionic acid monohydrate
Benzenepropanoic acid, α-hydrazinyl-3,4-dihydroxy-α-methyl-, (αS)-
CARBIDOPA 1-HYDRATE
benzenepropanoic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, (αS)-
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate (1:1)
MFCD00889211
benzenepropanoic acid, a-hydrazinyl-3,4-dihydroxy-a-methyl-, (aS)-
Benzenepropanoic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, (S)-
lodosyn
S-(-)-Carbidopa
(-)-L-a-Hydrazino-3,4-dihydroxy-a-methylhydrocinnamic Acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
Hydrazino-a-methyldopa

Biological Activity

[Description]:

Carbidopa ((S)-(-)-Carbidopa) monohydrate, a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa monohydrate is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa monohydrate inhibits pancreatic cancer cell and tumor growth[1][2].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> Aryl Hydrocarbon Receptor

Research Areas >> Neurological Disease

[In Vitro]

Carbidopa ((S)-(-)-Carbidopa) monohydrate exhibits activities similar to that described for other AhR ligands in BχPC3 and Capan-2 cells, namely the induction of CYP1A1 and CYP1A2, which are inhibited by AhR antagonists such as CH223191[1]. Carbidopa, a aromatic-L-amino acid decarboxylase inhibitor, is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Carbidopa is lethal (IC50=29 μM)[3].

[In Vivo]

Carbidopa monohydrate also induces nuclear uptake of the AhR, and in vivo studies show that carbidopa at a dose of 1 mg/mouse significantly inhibits tumor growth in athymic nude mice bearing BχPC3 cells as xenografts[1].

[References]

[1]. Safe S. Carbidopa: a selective Ah receptor modulator (SAhRM). Biochem J. 2017;474(22):3763-3765. Published 2017 Nov 6.

[2]. Fermaglich J. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa. Med Ann Dist Columbia. 1974;43(12):587-591.

[3]. Gilbert JA, et al. The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res. 2000;6(11):4365-4372.

Chemical & Physical Properties

[ Density]:
1.42 g/cm3

[ Boiling Point ]:
528.7ºC at 760 mmHg

[ Molecular Formula ]:
C₁₀H₁₆N₂O₅

[ Molecular Weight ]:
244.244

[ Flash Point ]:
273.5ºC

[ Exact Mass ]:
244.105927

[ PSA ]:
125.04000

[ LogP ]:
0.97380

MSDS

Click to get detail MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: MW5300000

CHEMICAL NAME :: Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate

CAS REGISTRY NUMBER :: 38821-49-7

LAST UPDATED :: 199707

DATA ITEMS CITED :: 8

MOLECULAR FORMULA :: C10-H14-N2-O4.H2-O

MOLECULAR WEIGHT :: 244.28

WISWESSER LINE NOTATION :: ZMX1&VQ2R &QH

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 4810 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Behavioral - ataxia

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 29,181,1974

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 352 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Behavioral - ataxia

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 29,181,1974

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 3428 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - other changes Skin and Appendages - hair

REFERENCE :: SKKNAJ Sankyo Kenkyusho Nempo. Annual Report of Sankyo Research Laboratories. (Sankyo K.K. Sogo Kenkyusho, 1-2-58 Hiro-machi, Shinagawa-ku, Tokyo 140, Japan) No.15- 1963- Volume(issue)/page/year: 28,116,1976

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1750 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Behavioral - ataxia

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 29,181,1974

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 148 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Behavioral - ataxia

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 29,181,1974

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 4955 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - ataxia Skin and Appendages - hair

REFERENCE :: SKKNAJ Sankyo Kenkyusho Nempo. Annual Report of Sankyo Research Laboratories. (Sankyo K.K. Sogo Kenkyusho, 1-2-58 Hiro-machi, Shinagawa-ku, Tokyo 140, Japan) No.15- 1963- Volume(issue)/page/year: 28,116,1976

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 519 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Behavioral - ataxia

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 29,181,1974

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: >600 mg/kg

TOXIC EFFECTS :: Behavioral - ataxia Lungs, Thorax, or Respiration - respiratory depression Kidney, Ureter, Bladder - hematuria

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 29,181,1974

Safety Information

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H319

[ Precautionary Statements ]:
P305 + P351 + P338

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
3

[ HS Code ]:
2932999099

Customs

[ HS Code ]: 2928000090

[ Summary ]:
2928000090 other organic derivatives of hydrazine or of hydroxylamine VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:20.0%

Articles

[(11)C]5-HTP and microPET are not suitable for pharmacodynamic studies in the rodent brain.

J. Cereb. Blood Flow Metab. 34(1) , 118-25, (2014)

The PET tracer [(11)C]5-hydroxytryptophan ([(11)C]5-HTP), which is converted to [(11)C]5-hydroxytryptamine ([(11)C]5-HT) by aromatic amino acid decarboxylase (AADC), is thought to measure 5-HT synthes...

Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems.

Eur. J. Drug Metab. Pharmacokinet. 39(4) , 237-42, (2014)

The objective of this study was to investigate the pharmacokinetic characteristics of levodopa (L-dopa) from nasal powder formulations using highly water-soluble levodopa methyl ester hydrochloride (L...

Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair.

Cancer Res. 74(21) , 6205-15, (2014)

Cancers due to germline mutations in the BRCA1 gene tend to lack targets for approved chemoprevention agents. This study aimed at a targeted chemoprevention strategy for BRCA1-associated malignancies....

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.